Table 2. CellCycler simulation results.
Simulation results in terms of diameter loss for the drugs as monotherapy and in combination.
| Drug schedule | Diameter loss |
|---|---|
| Taxol | |
| Day 1 weekly | 0.57 mm |
| EGFRi | |
| Days 1–5 every week | 0.90 mm |
| Taxol + EGFRi | |
| Taxol (Day 1) + EGFRi (Days 1–5) weekly | 1.38 mm |
| Taxol ->EGFRi: | |
| Taxol (Day 1) + EGFRi (Days 2–6) weekly | 1.44 mm |
| EGFRi ->Taxol: | |
| EGFRi (Days 1–5) + Taxol (Day 6) weekly | 1.31 mm |